|
WO2018213302A1
|
|
Compositions and methods for treating cancer with atypical braf mutations
|
|
EP3313186A1
|
|
Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
|
|
AU2016211246A1
|
|
Crystalline forms of C21H22CI2N4O2
|
|
US2016221988A1
|
|
Crystalline C21H22Cl2N4O2 malonate
|
|
US2017095575A1
|
|
Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
|
|
WO2015191623A1
|
|
Tem8 antibodies and methods of use
|
|
US2017112926A1
|
|
Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
|
|
US2017112928A1
|
|
Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
|
|
US2017101464A1
|
|
Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
|
|
WO2015191615A2
|
|
Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
|
|
US2017119882A1
|
|
Combination therapies targeting tumor-associated stroma or tumor cells
|
|
WO2015191590A2
|
|
Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
|
|
US2017119883A1
|
|
Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
|
|
AU2014368925A1
|
|
Cancer treatments using combinations of MEK type I and ERK inhibitors
|
|
WO2015095842A2
|
|
Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
|
|
WO2015095807A1
|
|
Cancer treatments using combinations of egfr and erk inhibitors
|
|
CA2934669A1
|
|
Cancer treatment using combinations of erk and raf inhibitors
|
|
WO2015095831A1
|
|
Cancer treatments using combinations of mtor and erk inhibitors
|
|
WO2015095825A1
|
|
Cancer treatments using combinations of type 2 mek and erk inhibitors
|
|
WO2015095834A2
|
|
Cancer treatments using erk1/2 and bcl-2 family inhibitors
|
